LA
APGN

Linden Advisors’s Apexigen, Inc. Common Stock APGN Stock Holding History

Linden Advisors’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-62,282
Closed -$624K – 824
2021
Q4 		$624K Buy
+62,282
New +$621K ﹤0.01% 528

Other funds holding APGN

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Linden Advisors's APGN Position: Q1 2022 in Review

Linden Advisors sold out of Apexigen, Inc. Common Stock (APGN) in Q1 2022, closing a stake of 62,282 shares — an estimated $624K sold.

Linden Advisors first reported a position in APGN in Q4 2021 and held it in 1 quarter. The position peaked at $624K in Q4 2021. 40 funds tracked by Wall St. Rank hold APGN as of Q1 2022.

  • Linden Advisors reported no remaining Apexigen, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Linden Advisors sold 62,282 Apexigen, Inc. Common Stock shares in Q1 2022, an estimated $624K.
  • Linden Advisors first reported a position in Apexigen, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Linden Advisors's Apexigen, Inc. Common Stock position peaked at $624K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q1 2022.

Based on Linden Advisors's 13F filing for Q1 2022, filed 16 May 2022.